CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

Rudolf Werner; Alexander Haug; Christian Buske; Simon Heidegger; Anna L. Illert; Florian Bassermann; Peter Herhaus; Andreas Buck; Johannes Duell; Max S. Topp; Sabrina Kraus; Hermann Einsele; Constantin Lapa; Markus Raderer; Georg Lenz; Stefan Habringer; Bastian von Tresckow; Ulrich Keller

doi:10.1055/a-2194-9965

CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L. Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S. Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastian von Tresckow, Ulrich Keller

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.

Translated title of the contribution	CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen
Original language	English
Pages (from-to)	57-61
Number of pages	5
Journal	NuklearMedizin
Volume	63
Issue number	2
DOIs	https://doi.org/10.1055/a-2194-9965
State	Published - 9 Aug 2023
Externally published	Yes

Keywords

CXCR4
T-cell lymphoma
[68Ga]Ga-PentixaFor
chemokine receptor
marginal zone lymphoma
theranostics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/a-2194-9965

Cite this

Werner, R., Haug, A., Buske, C., Heidegger, S., Illert, A. L., Bassermann, F., Herhaus, P., Buck, A., Duell, J., Topp, M. S., Kraus, S., Einsele, H., Lapa, C., Raderer, M., Lenz, G., Habringer, S., von Tresckow, B., & Keller, U. (2023). CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. NuklearMedizin, 63(2), 57-61. https://doi.org/10.1055/a-2194-9965

@article{f3ca9e7ad5204339af0e76251705d17c,

title = "CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges",

abstract = "C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.",

keywords = "CXCR4, T-cell lymphoma, [68Ga]Ga-PentixaFor, chemokine receptor, marginal zone lymphoma, theranostics",

author = "Rudolf Werner and Alexander Haug and Christian Buske and Simon Heidegger and Illert, {Anna L.} and Florian Bassermann and Peter Herhaus and Andreas Buck and Johannes Duell and Topp, {Max S.} and Sabrina Kraus and Hermann Einsele and Constantin Lapa and Markus Raderer and Georg Lenz and Stefan Habringer and {von Tresckow}, Bastian and Ulrich Keller",

note = "Publisher Copyright: {\textcopyright} 2024. The Author(s).",

year = "2023",

month = aug,

day = "9",

doi = "10.1055/a-2194-9965",

language = "English",

volume = "63",

pages = "57--61",

journal = "NuklearMedizin",

issn = "0029-5566",

publisher = "Georg Thieme Verlag",

number = "2",

}

TY - JOUR

T1 - CXCR4-targeted Theranostics in Hematooncology

T2 - Opportunities and Challenges

AU - Werner, Rudolf

AU - Haug, Alexander

AU - Buske, Christian

AU - Heidegger, Simon

AU - Illert, Anna L.

AU - Bassermann, Florian

AU - Herhaus, Peter

AU - Buck, Andreas

AU - Duell, Johannes

AU - Topp, Max S.

AU - Kraus, Sabrina

AU - Einsele, Hermann

AU - Lapa, Constantin

AU - Raderer, Markus

AU - Lenz, Georg

AU - Habringer, Stefan

AU - von Tresckow, Bastian

AU - Keller, Ulrich

PY - 2023/8/9

Y1 - 2023/8/9

N2 - C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.

AB - C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.

KW - CXCR4

KW - T-cell lymphoma

KW - [68Ga]Ga-PentixaFor

KW - chemokine receptor

KW - marginal zone lymphoma

KW - theranostics

UR - http://www.scopus.com/inward/record.url?scp=85182347008&partnerID=8YFLogxK

U2 - 10.1055/a-2194-9965

DO - 10.1055/a-2194-9965

M3 - Article

C2 - 38190998

AN - SCOPUS:85182347008

SN - 0029-5566

VL - 63

SP - 57

EP - 61

JO - NuklearMedizin

JF - NuklearMedizin

IS - 2

ER -

CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this